Seventy-four patients who have had biopsy of a non-palpable breast lesion are reviewed. A doubledye localization technique was used in 88% while in 12% localization of the lesion was best achieved by ultrasound mammography. Biopsy was successful in 70 patients (95%) at the first attempt. The overall incidence of malignancy was 20%, being greater in asymptomatic patients (32%) than in patients with mastalagia (16%). Re-excision of the biopsy site in these patients showed residual cancer in 33%. It is suggested that both careful examination of the operative specimen and postoperative mammography may be necessary to ensure that the original lesion has been removed. Re-excision of the biopsy site appears to be necessary when the histology is malignant.
Introduction
Improvements in mammography over 30 years have led to increasing detection of suspicious lesions within the breast which are not apparent on clinical examination 1,2. Conventional surgical methods are totally inadequate to deal with such lesions. Biopsy of a non-palpable lesion calls for close cooperation between different specialties if misdiagnosis of an early cancer as benign disease is to be avoided.
Localization of the lesion is of prime importance. Many different methods have been described.':", which reflects the difficulty ofaccurate localization, yet demand for such a procedure has steadily increased. Since a national programme of breast screening is to be introduced in the United Kingdom, the demand for localization biopsy will increase still further. Although screened patients will be treated at regional centres initially, it is likely that nonspecialist centres will sec cases also. We have reviewed our localization techniques (including the use of ultrasound) and the pathological findings to assess the problems of management of non-palpable breast lesions.
Patients and methods
Over a six-year period, 74non-palpable breast lesions were biopsied. Fifty-five patients (74%) attended a specialized breast clinic with symptomsthe greatest complaint being mastalgia. Symptomatic patients did not have a discrete breast lump but subsequent mammography revealed a suspicious area within the breast. Nineteen (26%) presented after screening mammography having no symptoms of breast disease.
X-ray localization
In 65 patients (88%) a double-dye localization method was used 5. By reference to the diagnostic mammograms, an injection of 0.5 ml methylene blue mixed with 0.75 ml iohexol (Omnipaque 350) is made into the breast at the point where the lesion is situated. Post-injection mammography demonstrates the precise relationship of the marker to the lesion and this is reported to the surgeon. Biopsy was carried out within two hours of the injection to avoid dye dispersal.
Ultrasound localization
Nine patients (12%) had localization with ultrasound sonomammography. Ultrasound is used in the investigation of most women with breast disease seen in our unit. Thus a solid, discrete lesion was found in 5 patients where conventional mammography had not been performed. In 2 women with X-ray dense breasts, ultrasound revealed a lesion not apparent on a mammogram. In a further 2 patients a suepicious area on mammography was more clearly defined by ultrasound and this was used for the localization procedure. For all ultrasound localizations a mark was placed on the skin directly over the lesion with the depth indicated.
Biopsy
All biopsies were. performed under general anaesthetic. A specimen X-ray was obtained to confirm the presence of the target lesion within the biopsy; the presence of marker dye in the specimen was not, by itself, regarded as a reliable indicator of a complete biopsy. The specimens were removed from the operating theatre for X-ray. The films were viewed by a radiologist and compared with the original mammogram. The surgeon was alerted if the biopsy appeared inadequate.
Results
The median age of the symptomatic and asymptomatic patients was the same (48 years) but the range in the asymptomatic group was smaller (asymptomatic group 40-62 years; symptomatic group 2&-85 years). Microcalcification was the indication for biopsy in 70% of patients, a mass lesion was present in 24% and architectural distortion, increased density and asymmetry were each present in a small proportion.
Biopsy was successful at the first attempt in 70 patients (95%). In 2 patients the target area was only partially excised and in 2 more an area of microcalcification was missed completely. The mean volume of tissue excised was 12 em", equivalent to a block 3 x 2 x 2 em, as measured after fixation in formalin. The mean diameter of the lesion was 0.8 em (range 0.3-2.0 em). The incidence of malignancy was 20%, with 4 patients having in-situ cancer and 11having invasive cancer. The pathologist reported that excision of malignancy was complete in 6 patients, incomplete in one and uncertain in 8. Four of these patients with uncertain excision had more than one focus of cancer in the biopsy specimen. Six of the cancers occurred in the 19 asymptomatic patients (giving a 32% incidence of malignancy in this group) and half of these were of the in-situ type. Nine cancers occurred in the symptomatic patients (incidence of malignancy 16%), one being in-situ and 8 invasive (Figure 1) .
Of the 59 patients with benign disease the majority (54%) were reported as having fibroadenosis or fibrocystic disease. Nine patients (15%) had epithelial hyperplasia.
In patients with cancer the original biopsy site was widely excised in 6, and mastectomy performed in 9. Residual cancer was found in 5 patients who had further surgery ( Figure 2 ). In 3 cases this was in the wall of the biopsy cavity, and all had been predicted by the pathologist, whereas 2 patients had a separate focus of intraduct cancer. One of these had uncertain excision in the original biopsy. Residual cancer in one patient showed areas of invasion, while the original biopsy contained only in-situ cancer, and this patient is included in the 11 with invasive cancer. Patients having wide excision or no further surgery received postoperative radiotherapy. Nine of the patients with invasive cancer had axillary dissection. Lymph node metastases were present in 2 (22%). One patient had radiotherapy and one patient had no treatment of the axilla because of advanced age.
Discussion
Complete surgical eXCISIOn of a non-palpable breast lesion requires accurate localization. A totally reliable technique has yet to be found. We prefer a double-dye technique for logistical reasons -there is no risk of the marker being displaced while the patient is in transit between radiology and operating departments. The major problem in localization is the difficulty in placing the marker exactly at the site of the lesion, perhaps more so with the double-dye method than with wire markers. Where the marker lies adjacent to the lesion, the surgeon must estimate to a greater or lesser degree which part of the breast contains the target. Not uncommonly the biopsy will consist of more than one piece of breast tissue. If a marker wire is removed with the first piece, as it should be, further biopsy becomes even more difficult. This may be an advantage of the double-dye localization method.
We have found sonomammography to be useful in the investigation of women with symptomatic breast disease". Ultrasound localization has not been reported previously. Where a suspicious breast lesion is clearly seen on X-ray, then mammographic localization is likely to be more accurate than ultrasounddirected biopsy with a surface marker. However, not only can ultrasound detect non-palpable lesions but it may do so in cases where X.ray mammography 'sees' the lesion poorly. In these situations ultrasound localization is invaluable.
Only a small proportion of reports include the numbers of failed biopsies. We missed 5% of nonpalpable lesions and this is similar to the experience of others'':". As the chance of the lesion being an early cancer is approximately 1 in 3 for screened patients and 1 in 5 for those with symptoms, it is essential that patients who have a failed biopsy are identified. The first check should be made by the surgeon. In a small piece of tissue a previously non-palpable lesion may become palpable. Sectioning the biopsy may aid this, but all excised tissue should be sent for histology due to the risk of multi-focal disease. In some centres the pathologist receives the specimen in the operating theatre so that he too may identify the suspicious areas. Ifthe lesion can be felt in the biopsy tissue, the surgeon will have the best opportunity to confirm complete excision. Pathological sectioning may make the completeness of excision difficult to determine. In only half our patients where microscopic examination did not confirm complete excision was residual disease found.
Removal of only part of the lesion occurs more frequently than a completely missed biopsy'. If the pathology of the excised tissue is benign, it cannot be assumed that the remainder of the lesion is benign also. Cancer can occur adjacent to an area of microcalcification -especially ifit has a scattered appearanca". This well recognized occurrence suggests that cases of partial biopsy require reoperation. If not, the patient should be followed up carefully with mammography.
Specimen X-ray is mandatory, but may poorly demonstrate a lesion that does not contain calcification. Transportation of the specimen to the X-ray department causes delay, and a self-contained specimen X-ray unit in the operating department is preferable!". A specimen X-ray should show that the target lesion is contained within the biopsy, but it is generally unhelpful in confirming complete excision 
BIOPSY
because it looks at the specimen in one plane only. Occasionally, as in our 2 cases of missed biopsy, there may be some calcification in the specimen radiograph which is not the target lesion, thus giving falsepositive confirmation of excision. Postoperative mammography at 4-6 weeks should therefore be considered in every patient in whom the pathology is benign I 1.
When a non-palpable lesion is malignant, wide excision of the biopsy site, even if the tumour is noninvasive, appears to be essential. Our finding of a high level of residual cancer is similar to that in other seriea'P, A second focus or multiple foci of cancer in the breast is a common finding, ranging between 33% and 39%, including patients with in-situ cancers12.13. Thus we have treated the remaining breast with radiotherapy following wide excision or by mastectomy. Lymph node metastases have been reported in 4-38% of patients with a non-palpable primary tumour":". In-situ cancers, by definition, should not metastasize and this is our experience. Nodal metastasis associated with intraduct carcinoma has been reported rarely and could be due to a separate, undiagnosed focus of invasive cancer being present in the breast. It is now our policy not to treat the axilla in patients with noninvasive cancer.
Overall, patients with non-palpable cancer should have a better prognosis than those with overt cancer because of the smaller tumour size. Large studies of breast screening have also shown early detection to be ofbenefi t 14.1 s. The management ofsuspicious nonpalpable breast lesions requires close cooperation between radiologist and surgeon to achieve accurate and complete biopsy. Similarly, there must be cooperation between pathologist and surgeon in order to confirm complete excision and determine the best treatment for each patient with cancer. A method of detecting any patient whose biopsy is inadequate should be employed until a totally reliable localization biopsy technique is available.
